Bavarian Nordic A/S announced Thursday that the Company has secured a contract with an undisclosed European country to supply its IMVANEX® smallpox vaccine in response to new cases of monkeypox evolving during May 2022.
Bavarian Nordic’s smallpox vaccine is approved in the U.S. as JYNNEOS® and in Canada as IMVAMUNE®, both places with the approval extended to cover the monkeypox indication. The vaccine is approved in Europe as IMVANEX® for only the smallpox indication but has previously been provided for off-label use in response to monkeypox cases.
Paul Chaplin, President and CEO of Bavarian Nordic said: “While the full circumstances around the current monkeypox cases in Europe remain to be elucidated, the speed of which these have evolved, combined with the potential for infections beyond the initial case going undetected, calls for a rapid and coordinated approach by the health authorities, and we are pleased to assist in this emergency situation. Infection control has been a high priority for societies during COVID-19, and this situation is an unfortunate reminder, that we cannot let our guard down, but must continue to build and strengthen our infectious disease preparedness to keep the world open.”
Monkeypox is a rare, but serious disease, which is endemic in Central and West Africa. The disease is quite similar to human smallpox, although it is less severe with an estimated fatality rate of 1-10%.
- France reports first confirmed case of monkeypox
- Singapore closes in on 10,000 dengue cases
- Fiji reports more than 2000 lab-confirmed leptospirosis cases year to date
- England monkeypox cases now total 20, ‘We expect this increase to continue in the coming days’
- Canada: Two monkeypox cases confirmed in Quebec
- Spain: 7 confirmed monkeypox cases reported in the Community of Madrid
- Portugal monkeypox update: 23 confirmed cases
- Australia reports two monkeypox cases- One in Victoria and one in New South Wales